A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy

Author(s):  
Atsushi Naganuma ◽  
Yuhei Suzuki ◽  
Takashi Hoshino ◽  
Hidetoshi Yasuoka ◽  
Yuki Tamura ◽  
...  
2009 ◽  
Vol 16 (4) ◽  
pp. 508-512 ◽  
Author(s):  
Wing-Hong Li ◽  
Edmond Cheung-Yan Cheuk ◽  
Philip Chong-Hei Kowk ◽  
Moon-Tong Cheung

2017 ◽  
Vol 11 (1) ◽  
pp. 155-161
Author(s):  
Severin Gloor ◽  
Kai Oliver Jensen ◽  
Stefan Breitenstein ◽  
Christoph A. Binkert ◽  
Eliane Angst ◽  
...  

Spontaneous ruptures of hepatocellular carcinoma (HCC) are rare. Nevertheless they may lead to difficult decisions in the emergency situation. The acute therapies include conservative treatment, transarterial embolization and surgery. Curative treatment of HCC can be achieved by liver resection solely. The decision-making depends on prognostic patient’s factors, such as hepatic viral infection status, Child-Pugh grade, liver cirrhosis and number of tumors. In this case transarterial embolization was preferable as a bridging therapy prior to further diagnostics and therapy, to lower the perioperative morbidity and mortality. The therapy of these cases needs an interdisciplinary approach to choose the best possible procedure in each case.


2020 ◽  
Vol 06 (02) ◽  
pp. e112-e117
Author(s):  
Gunjan S. Desai ◽  
Prasad M. Pande ◽  
Rajvilas A. Narkhede ◽  
Prasad K. Wagle

AbstractA 59-year-old gentleman with a history of aortic valve replacement presented with spontaneously ruptured hepatocellular carcinoma in right lobe of a hepatitis C virus (HCV)-related chronic liver disease with hemoperitoneum. This acute emergency was managed by transarterial embolization. Right trisectionectomy with preservation of segment IVB after augmentation of future liver remnant by transarterial chemoembolization followed by portal vein embolization was subsequently performed. Sustained virological response to HCV was attained after surgery using sofosbuvir-based regimen. He had a delayed operative bed recurrence 1.5 years later with pulmonary metastatic disease which was managed by operative bed metastasectomy with mesh reconstruction of diaphragm and sorafenib. He is on sorafenib since past 3 years and doing well at 4.5-years follow-up since the first presentation, with significant regression of pulmonary disease and no other disease elsewhere, which highlights that where there is hope, there is a way.


Sign in / Sign up

Export Citation Format

Share Document